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SKF-99085 ethyl-1,1-diphosphonate] is an orally active inhibitor of acylCoAxholesterol acyltransferase (ACAT), the enzyme responsible for the acylation of cholesterol to cholesteryl esters. It has been postulated that inhibition of this enzyme could prevent excess accumulation of cholesteryl esters, resulting in suppression of atheromatous plaque formation in the intima of arterial walls (Matsuda, 1994) . SKF-99085 also exhibits calcium chan-1 Current address: Eisai Research Institute, Andover, MA.
nel blocking activity and antioxidant properties that are considered useful characteristics of an antiatherosclerotic agent.
SKF-99085 was evaluated in rats in single dose and repeat dose toxicity studies of up to 6 months duration as part of the preclinical assessment of this drug candidate. In a 6-month toxicity study, 6 of 12 male rats given doses of 400 mg/kg/day SKF-99085 died or were killed in moribund condition during the first 3 months of the study. Hemorrhage was observed in various tissues at necropsy. The purpose of this study was to further characterize this drug-related hemorrhagic disorder.
MATERIALS AND METHODS

Animals.
Male and female Sprague-Dawley virus-antibody-free rats (Charles River Laboratories, Raleigh, NC) were used in this study. The rats were approximately 11 weeks of age and weighed between 322 and 403 g (males) or 197 and 245 g (females) at the start of dosing. Rats were housed individually in stainless steel cages in a controlled environment (72 ± 4°F: 50 ± 10% relative humidity) with a 12-h light/dark cycle. Male and female rats were offered at least 21 or 16 g per day, respectively, of 5002 Certified Rodent Diet and 2.5 g SK 5L34 (PMI Feeds, Inc., St. Louis, MO). Food was withheld prior to blood collection at necropsy. Filtered tap water was available ad libitum. All animal care procedures were in accordance with the Guidelines for the Use and Care of Laboratory Animals, NIH Publication No. 86-23 (U.S. Department of Health and Human Services, Bethesda, MD).
SKF-99085. SKF-99085 was administered orally by gavage (10 ml/kg) as a suspension in 1% aqueous carboxymethylcellulose to male and female rats (12/sex/group) at dosages of 0 (vehicle), 10, 100, or 400 mg/kg/day for 26 weeks.
Plasma samples. Blood was collected for coagulation testing from control and drug-treated rats prior to the daily dose at weeks 6, 17, and 24 of the study and at necropsy (week 26). Rats were restrained in a heating apparatus for approximately 5 min to dilate the tail vein for blood collection. A 21-gauge, 3/4-in. butterfly needle was inserted into the lateral tail vein, and approximately 0.9 ml of blood was allowed to flow into tubes (Teklab Medical Laboratories Ltd., Durham, UK) containing trisodium citrate (0.13 M, 1 part anticoagulant per 9 parts blood). At necropsy, blood samples were collected from the vena cava into 10-ml plastic syringes, and 4.5 ml of blood was transferred immediately to citrated Vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ) and inverted gently. Blood samples were centrifuged at 4°C at 900# for approximately 15 min, and citrated plasma was removed and refrigerated for immediate testing or recentrifuged as indicated above and frozen at approximately -70°C until assayed.
Measurements. Prothrombin time (PT) and activated partial thromboplastin time (APTT) and coagulation factors n, V, VTi, Vm, EX, and X were measured using the Electra 1000C Automatic Coagulation Timer (Medical Values for activated partial thromboplastin time (APTT), prothrombin time (PT), and Thrombotest clotting time (TCT) expressed as means ± SE, n = 10 to 12, except n = 6 for males given 400 mg/kg. * Difference from control is statistically significant at P < 0.05. " Difference from control is statistically significant at P < 0.0001.
Laboratory Automation, Pleasantville, NJ). Assays for PT and APTT were run in accordance with the manufacturer's specifications using rabbit brain thromboplastin with calcium (Dade Thromboplastin C, Baxter Diagnostics, Inc., Deerfield, IL) or a liquid rabbit brain cephalin (Dade Actin, Baxter Diagnostics, Inc.) with 0.02 M calcium chloride, respectively. A four-point standard curve (1:10 to 1:80) was prepared for each factor using a citrated plasma pool (vena cava) from age-matched Sprague-Dawley rats. Plasma samples were diluted 1:10 in Owren's Veronal buffer prior to testing. Human immunoadsorbed factor-deficient plasma (Dade, Baxter Diagnostics, Inc.) was used as the substrate plasma. The Thrombotest clotting time (Nycomed UK Ltd., Birmingham, England) was measured in duplicate by a tilt-tube method following addition of Thrombotest reagent (755 (il) to citrated plasma (10 jil).
Statistical analysis. All statistical tests were performed at the overall Type I error rate of 5% unless otherwise stated. Pairwise comparisons of PT and APTT using nonparametric analyses based on ranks (Conover, 1980) were performed to evaluate differences between active doses and control. For the TCT, the log-rank test was performed to evaluate statistically significant trends across the four dose groups followed by pairwise comparisons of the active dose groups against the control. Dunnett's test was used for pairwise comparisons of active groups against control for coagulation factor activity (Tukey et al., 1985) . In addition, a Jonkheere nonparametric test was performed to determine dose-related trends (Jonckheere, 1954) .
RESULTS
Six of 12 male rats given 400 mg/kg/day SKF-99085 died or were killed in moribund condition during the first 3 months of dosing. Death in these animals was attributed to a hemorrhagic disorder as evidenced by clinical findings, such as paleness and bleeding from external wounds and the presence of hemorrhage in various tissues at necropsy. Blood for evaluation of hemostasis parameters was collected from surviving male and female rats to investigate the bleeding disorder.
Mean values for APTT, PT, and Thrombotest clotting time (TCT) for male and female rats given doses of 0, 10, 100, or 400 mg/kg/day SKF 99085 (week 24) are shown in Table 1 . Statistically significant increases (P < 0.05) in APTT and TCT were observed beginning at week 6 in male rats given si00 mg/kg/day SKF 99085 and at week 24 in male rats given 10 mg/kg/day. At doses of 10, 100, and 400 mg/kg/day, respectively, mean APTT values during the study ranged from 16.5 to 17.5, 18.9 to 20.8, and 25.7 to 34.7 s (control, 15.4 to 16.0 s).
Mean PT were significantly increased (P < 0.05) to 14.3-16.5 s (control, 12.9-13.1 s) only at a dose of 400 mg/kg/day. There was a statistically significant increase (P < 0.0001) in TCT in male rats given 2:10 mg/kg/day SKF 99085 at weeks 17 and 24; mean TCT values ranged from 84 to 86, 82 to 100, and 259 to >300 s (control, 71-74 s) at doses of 10, 100, or 400 mg/kg/day, respectively. There were no remarkable changes in hemostasis parameters in female rats.
At week 26, activities of plasma coagulation factors II and LX for male rats given > 10 mg/kg/day SKF 99085 and activity of factors VTI and X for male rats given 400 mg/kg/day were significantly decreased (P < 0.05) compared to control values (Fig. 1) . Activities of factors V and VIII were not significantly affected.
DISCUSSION
Increased prothrombin and activated partial thromboplastin times (weeks 6,17, and 24), Thrombotest clotting times (weeks 17 and 24), and decreased plasma coagulation factor II, VII, LX, and X activities (week 26) were observed in male drugtreated groups. The increase in APTT values was explained by a decrease in the activities of factors LX and X, and the increase in TCT was consistent with decreases in activities of factors II, VII, LX, and X; decreases in the activity of these coagulation factors have been associated with vitamin K deficiency in the rat (Godsafe et al, 1992) .
The APTT and TCT were more sensitive than the PT in monitoring for reductions in vitamin-K-dependent coagulation factor activities in this study. Dose-related increases in APTT and TCT were observed at doses ^ 10 mg/kg/day to maximums of 2-and 4-fold, respectively, in male rats given 400 mg/kg/ day. The PT for male rats given 400 mg/kg/day SKF 99085 was minimally increased (1.2-fold), despite a marked reduction in activity (10-20% control) of coagulation factors n, VII, LX, andX.
The relative insensitivity of the prothrombin time for the detection of the reduced vitamin-K-dependent coagulation fac- Effects on plasma activity for coagulation factors n, V, VII, VHI, IX, and X at week 26 for male rats given SKF-99085 at dosages of 10, 100, or 400 mg/kg/day (n = 12, 11, or 6, respectively). Each bar represents the mean percentage ± SE of vehicle control factor activity (expressed as 100%).
•Significantly different from control (P < 0.05).
tor activity is in contrast to observations in dogs and humans. Because the PT is sensitive to reductions in three of the four vitamin-K-dependent coagulation factors (II, VII, and X), it is used widely in human medicine to monitor for effects on these factors in patients undergoing oral anticoagulant (coumarin) therapy (Hirsh et al., 1994) and in veterinary medicine in the detection of warfarin toxicity (Hall, 1972) .
It is possible that the rabbit brain thromboplastin reagent used in this PT assay is less sensitive to alterations in rat coagulation factor activity. Animal plasmas frequently clot very rapidly in assays utilizing commercial rabbit brain reagents, resulting in an inability to detect minor deficiencies in coagulation factor activity. Some laboratories have enhanced the sensitivity of this assay by diluting the commercial reagent to produce a longer "normal" clotting time (Dodds, 1989) . Human brain thromboplastin has been found to be more sensitive to some animal factor deficiencies than other thromboplastins (Mifsud, 1979) . The Thrombotest has been shown to be more sensitive than the PT in the detection of reductions in vitamin-K-dependent coagulation factor activities in rats (Godsafe et al., 1992) . In this laboratory, a modification of the Thrombotest assay (1:76.5 rather than a 1:51 plasma dilution) may have also contributed to the enhanced sensitivity of the assay.
The hemorrhagic bleeding disorder observed in male rats given 400 mg/kg/day SKF 99085 was attributed to a deficiency in the activity of vitamin-K-dependent coagulation factors II, VII, IX, and X. The plasma activity of factors II, VII, IX, and X decrease dramatically, particularly in male rats, in the absence of dietary vitamin K (Godsafe et al., 1992) . The mechanism of the effect on vitamin-K-dependent factors in this study may be related to alterations in absorption or metabolism of vitamin K following treatment with the ACAT inhibitor. Vitamin K is lipid soluble, its absorption is facilitated by the presence of dietary fat and bile acids, and it is incorporated into and transported by plasma lipids (Newberne and Conner, 1989) . The ACAT enzyme is responsible for the acylation of cholesterol to cholesteryl esters, and it has been suggested that ACAT inhibitors decrease cholesterol absorption and increase cholesterol excretion by the liver (Matsuda, 1994) .
Male rats were more susceptible than female rats to the deficiency in vitamin K dependent coagulation factor activities in this study. This finding is consistent with the known protective effect of estrogens and the accentuating effects of testosterone on the development of vitamin K deficiency in rats (Matschiner and Willingham, 1974; Uchida et al, 1985; Jolly et al., 1977; Hara et al., 1994) . No evidence of a coagulation abnormality was observed in male or female dogs given SKF-99085 at doses up to 100 mg/kg/day for 6 months. The known sensitivity of male rats to vitamin K deficiency, the observation of significant coagulation effects in male rats at only the highest dose administered (400 mg/kg), and the lack of coagulation effects in female rats and male and female dogs suggest that coagulation abnormalities are unlikely to occur in humans treated with SKF-99085.
In summary, the drug-related hemorrhagic disorder observed in male rats given high doses of the ACAT inhibitor SKF 99085 was attributed to a reduction in the activity of vitamin-K-dependent coagulation factors. In contrast to humans and some other species, the APTT and TCT were more sensitive screening tests than the PT in detecting deficiencies of vitamin-K-dependent coagulation factors.
